User profiles for Julie Bertrand
Julie BertrandINSERM Verified email at inserm.fr Cited by 1334 |
Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load
We modeled the viral dynamics of 13 untreated patients infected with severe acute respiratory
syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral …
syndrome‐coronavirus 2 to infer viral growth parameters and predict the effects of antiviral …
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
The relationship between SARS-CoV-2 viral load and infectiousness is poorly known. Using
data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of …
data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of …
A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status
S Reeves, J Bertrand, SJ Obee… - British Journal of …, 2024 - Wiley Online Library
Aims Guidance on clozapine dosing in treatment‐resistant schizophrenia is based largely
on data from White young adult males. This study aimed to investigate the pharmacokinetic …
on data from White young adult males. This study aimed to investigate the pharmacokinetic …
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose–response models
Estimation methods for nonlinear mixed-effects modelling have considerably improved over
the last decades. Nowadays, several algorithms implemented in different software are used. …
the last decades. Nowadays, several algorithms implemented in different software are used. …
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease
See Caravaggio and Graff-Guerrero (doi: 10.1093/awx023 ) for a scientific commentary on
this article. Antipsychotic drugs, originally developed to treat schizophrenia, are used to treat …
this article. Antipsychotic drugs, originally developed to treat schizophrenia, are used to treat …
Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS …
J Bertrand, C Verstuyft, M Chou… - The Journal of …, 2014 - academic.oup.com
We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307
patients coinfected with human immunodeficiency virus and tuberculosis and included in …
patients coinfected with human immunodeficiency virus and tuberculosis and included in …
[HTML][HTML] The Proust Machine: What a Public Science Event Tells Us About Autobiographical Memory and the Five Senses
Our senses are constantly stimulated in our daily lives but we have only a limited understanding
of how they affect our cognitive processes and, especially, our autobiographical memory…
of how they affect our cognitive processes and, especially, our autobiographical memory…
Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters
We evaluate by simulation three model-based methods to test the influence of a single
nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA…
nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA…
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients
M Chou, J Bertrand, O Segeral, C Verstuyft… - Antimicrobial agents …, 2010 - Am Soc Microbiol
The aims of this ANRS12154 open-label, single-center, multiple-dose pharmacokinetic
study were to characterize nevirapine pharmacokinetics in a Cambodian population of HIV-…
study were to characterize nevirapine pharmacokinetics in a Cambodian population of HIV-…
Development of a complex parent-metabolite joint population pharmacokinetic model
This study aimed to develop a joint population pharmacokinetic model for an antipsychotic
agent in development (S33138) and its active metabolite (S35424) produced by reversible …
agent in development (S33138) and its active metabolite (S35424) produced by reversible …